Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B - Trial NCT05770895
Access comprehensive clinical trial information for NCT05770895 through Pure Global AI's free database. This Phase 1 trial is sponsored by Gilead Sciences and is currently Recruiting. The study focuses on Chronic Hepatitis B. Target enrollment is 70 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Gilead Sciences
Timeline & Enrollment
Phase 1
Apr 03, 2023
Nov 01, 2024
Primary Outcome
Percentage of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs),Percentage of Participants With Treatment-emergent Laboratory Abnormalities
Summary
The goal of this clinical study is to learn more about GS-2829 and GS-6779 in healthy
 participants and participants with CHB.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05770895
Non-Device Trial